KIDINS220 Variant Screening for ESRD Risk in Obese Patients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective predictors for the progression of end-stage renal disease (ESRD), particularly in obese individuals, necessitating a better understanding of genetic contributors like KIDINS220 mutations to improve risk stratification and intervention.
Innovation Solution
A method is developed to identify high-risk subjects for ESRD by detecting KIDINS220 variants in body fluid samples, integrating this into existing genetic panels to enhance predictive accuracy and guide targeted treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing genetic panels are used for renal disease screening, then a baseline level of prediction is achieved, but the predictive accuracy remains insufficient for identifying high-risk patients who will progress to ESRD
Solution Approach 1:
The patent segments the genetic testing approach by separating existing renal disease genes from the novel KIDINS220 gene pathway. This segmentation allows the invention to add specific predictive capability for ESRD progression without replacing the entire genetic panel, thereby improving measurement precision while maintaining the reliability of existing renal disease predictions.
Solution Approach 2:
The KIDINS220 gene acts as an intermediary marker that bridges the gap between current renal disease diagnostics and ESRD prediction. By introducing this novel genetic marker, the patent enhances predictive accuracy without fundamentally altering the existing diagnostic framework, thus improving measurement precision while preserving the reliability of current renal disease identification.
2Measurement precision
If comprehensive genetic testing is expanded to include novel pathways, then predictive accuracy for ESRD progression improves, but the complexity and cost of testing increases
Solution Approach 1:
The patent segments the genetic testing panel by adding KIDINS220 as a separate, focused component rather than requiring a complete genomic rework. This segmented approach improves predictive accuracy for ESRD progression while keeping the overall testing framework manageable and not excessively complex.
Solution Approach 2:
The patent applies partial action by selectively adding only the KIDINS220 gene to existing panels rather than implementing comprehensive whole-genome sequencing. This partial expansion improves predictive accuracy for the specific outcome of ESRD progression while avoiding the excessive complexity and cost of complete genomic testing.
3Productivity
If genetic testing is performed on all patients, then more patients benefit from early identification, but the cost and resource burden on healthcare systems increases
Solution Approach 1:
The patent enables preliminary action by identifying high-risk patients through the KIDINS220 genetic marker before they progress to ESRD. This allows targeted intervention in a subset of patients most likely to benefit, increasing the number of patients identified with early-stage disease while avoiding the resource burden of universal testing.
Solution Approach 2:
The patent applies local quality by tailoring genetic testing to specific patient populations at highest risk for ESRD progression rather than applying it uniformly to all patients. This localized approach increases the number of beneficial identifications while reducing the overall quantity of testing resources required.
Data Source
AI summary
A method of evaluating a subject for a renal condition, wherein the subject is obese or severely obese, and treating the subject based on the evaluation, the method comprising the steps of (1) performing an assay configured to detect a non-benign Kinase D-interacting substrate of 220 kDA (KIDINS220) variant protein in a body fluid sample obtained from the subject; (2) determining that the subject has an elevated risk for end-stage renal disease (ESRD) when one or more non-benign KIDINS220 variants are present in the body fluid sample; and (3) treating the subject having the elevated risk for ESRD with a compatible kidney treatment regimen.